6. References

Akasu M, Urata H, Kinoshita A. Difference in tissue angiotensin II forming pathways by species and organs in vitro. *Hypertension* 1998; 32: 514-520

Armstrong Armstrong D, Jepson JB, Keele CS Stewart JW: Development of pain-producing substances in human plasma. *Nature* 1954 ; 174: 791-792

Anversa P, Nadal-Ginard B. Myocyte renewal and ventricular remodelling. *Nature* 2002; 415: 240-243

Austin KE, Faussner A, Robinson HE, Chakravarty S, Kyle DJ, Bathon JM, Pround D. Stable expression of the human B1 receptor in Chinese hamster ovary cells. *J Biol Chem* 1997; 272: 11420-11425

Balligand JL, Ungureanu D, Kelly R, Kobzik L, Pimental D, Michel I et al. Abnormal contractile function due to induction of nitrix oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditional medium. *J Clin Invest* 1993; 91: 2314-19

Barbul A. Immune aspects of wound repair. *Clin Plastic Surg* 1990; 17: 433-442

Baruch L, Anand I, Cohen IS, Ziesches S, Judd D, Cohn JN, for the Vasodilator Heart Failure Trial (V-HeFT) Study Group. Augmented short- and long- term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. *Circulation* 1999; 99: 2658-2664

Baumgarten CR, Linz W, Kunke G, Schölkens BA, Wiemer G. Rampiprilat increases bradykinin outflow from isolated rat hearts. *N Engl J Med* 1993; 108: 293-295

Becker RHA, Wiemer G, Linz W. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. *J Cardiovasc Pharmacol* 1991; 18 (Suppl 2): S110-S115

Beltrami AP, Urbanek K, Kajstura J, Yan SM, Finato N, Bussani R, Nadal-Ginard B, Silvestri F, Leri A, Beltrami CA, Anversa P. Evidence that human cardiac myocytes divide after myocardial infarction. *N Engl J Med* 2001; 344: 1750-7

Bhoola KD, Figueroa CD, Worthy K, Bioregulation of kinins: kallikreins, kininogens, and kininases. *Pharmacol Rev* 1992; 44: 1-80

Blais CJ, Drapeau G, Raymond P. Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study. *Am J Physiol* 1997; 273: H2263-H2271

Blum A. Samuel Sclarovsky S, Rehavia E, Shohat B, Tiqva P, Aviv T. Levels of T-lymphocyte subpopulations, interleukin-1ß, and soluble interleukin-2 receptor in acute myocardial infarction. *Am Heart J* 1994; 127: 1226-1230

Blum A. Interleukin 1 in acute myocardial infarction. *The Lancet* 1996; 347: 56

Boluyt MO, O'Neill L, Meredith AL, Bing OH, Brooks WW, Conrad CH, Crow MT, Lakatta EG. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure: marked upregulation of genes encoding extracellular matrix components. *Circ Res* 1994; 75: 23- 32

Calixto JB, Cabrini DA, Ferreira J and Campos MM. Knins in pain and inflammation. *Pain* 2000; 87: 1-5

Campbell DJ, Kladis A, Duncan AM. Bradykinin peptides in kidney, blood and other tissues of the heart. *Hypertension* 1993; 21: 155-65

Carretero OA, Miyazaki S, Scili AG. Role of kinins in the acute hypertensive effect of the converting enzyme inibitor, captopril. *Hypertension* 1981; 3: 18-22

Christopher J, Velarde V, Zhang D, Mayfield D, Mayfield RK, Jaffa A. Regulation of B2-kinin receptors by glucose in vascular smooth muscle cells. *Am J Physiol* 2001; 280: H1537-H1546

CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). *N Engl J Med* 1987; 316: 1429-35

Couture R, Harrisson M, Vianna RM, Cloutier F. Kinin receptors in pain and inflammation. *Eur J Pharmacol* 2001; 429 (1-3): 161-76

Davis AJ, Perkins MN. The involvement of bradykinin B1 and B2 receptor mechanisms in cytokine-induced mechanical hyperalgesia in the rat. *Br J Pharmacol* 1994; 113: 63-68

Decarie A, Raymond P, Gervais N, Couture R, and Adam A, Serum interspecies differences in metabolic pathways of bradykinin and [des-Arg9]BK: influence of enalaprilat. *Am J Physiol* 1996; 271: H1340-H1347

de Freitas FM, Farraco EZ, de Azevedo DF: General circulatory alterations induced by intravenous infusion of synthetic bradykinin in man. *Circulation* 1964; 29: 66-70

de Weerd WF, Leeb-Lundburg LM. Bradykinin sequesters B2 bradykinin receptors and the receptor-coupled G α subunits and in in carveolae in DDT1 MF-2 smooth muscle cells. *J Biol Chem* 1997; 272: 17858-17866

Dixon BS, Sharma RV, Dennis MJ. The bradykinin B2 receptor is a delayed early response gene for platelet-derived growth factor in arterial smooth muscle cells. *J Biol Chem* 1996; 271(23):13324-32

Dray A, Perkins M. Bradykinin and inflammatory pain. *Trends Neurosci* 1993; 16: 99-104

Duncan AM, Burell LM, Kladis A, Campbell DJ. Effects of angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction. *J Cardiovasc Pharmacol* 1996; 28: 746-54

Ertl G, Kloner RA, Alexander RW, Braunwald E. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. *Circulation* 1982; 65: 40-48

Farhy RD, Carretero OA, Ho K-L, Scicli AG. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. *Circ Res* 1993; 72: 1202-1210

Faussner A, Bathon JM, Proud D. Comparison of the responses of B1 and B2 kinin receptors to agonist stimulation *Immunopharmacology* 1999; 45: 13-20

Faußner A, Heinz-Erian P, Klier C, Roscher AA. Soluabilization and charicterization of B2 bradykinin receptors from cultured human fibroblasts. *J Biol Chem* 1991; 266: 9442-9446

Fujiwara Y, Mantione CR, Yamaura HI. Identification of B2 bradykinin receptor binding sites in guinea pig brain. *Eur J Pharmacol* 1988; 147: 487-488

Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. *N Engl J Med* 1998; 339: 1285–1292

Galizzi JP, Bodinier MC, Chapelain B, Ly SM, Coussy L, Giraud S, Neliat G, Jean T. Up-regulation of [3H]-des-Arg^{10}-kallidin binding to the bradykinin B1 receptor by interleukin-1 beta in isolated smooth muscle cells: correlation with B1 agonist-induced PGI_2 production. *Br J Pharmacol* 1994; 113(2): 389-94

Gohlke P, Linz W, Scholkens BA, Kuwer I, Bartenbach S, Schnell A and Unger T. Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradyinin. *Hypertension* 1994; 23: 411-418

Guillen I, Blances M, Gomez-Lechon MJ, Castel JV. Cytokine signaling during acute myocardial infarction: sequential apperance of IL-1 beta and IL6. *Am J Physiol* 1995; 269: R229-R235

Haasemann M, Figueroa CD, Henderson L, Grigoriev S, Abd Alla S, Gonzalez CB, Dunia I, Hoebeke J, Jarnagin K, Cartaud J, Bhoola KD, Müller-Ersterl W. Distribution of kinin B2 receptors in cultured cells, blood cells, and tissue sections. *Braz J Med Biol Res* 1994; 27: 1739-1756

Hall JM. Bradykinin receptors: Pharmacological properties and biological roles. *Pharmacol Ther* 1992; 56: 131-190

Hansson GH. Immune and inflammatory mechanism in the development of atheroscerosis. *Br Heart J* 1993; 69 (suppl): S38-41

Hartman JC, Wall TM, Hullinger TG, Shebuski RJ. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. *J Cardiovasc Pharmacol* 1993; 21: 996-1003

Haschimoto K, Hamamoto, H, Honda Y, Hirose M, Furukawas S & Kimura. Changes in components of kinin system and hemodynamic in acute myocardial infarct. *Am Heart J* 1978; 95: 619-626

Hecker M, Bara AT, Busse R. Potentiation of the biological efficacy of bradykinin by ACE inhibitors: a shift in the affinity of the B2 receptor? *Immunopharmacology* 1996; 33: 93-4

Herskowitz A, Choi S, Ansari AA, Wesselingh S. Cytokine mRNA expression in postmyoischemic/reperfused myocardiom. *AM J Pathol* 1995; 146: 419-428

Hosenpud JD, Campbell SM, Mendelson DJ. Interleukin 1 induced myocardial depression in an isolated beating heart preparation. *J heart Transplant* 1989; 8: 460-464

Keravis TM, Nehlig H, Delacroix MF, Regoli D, Hiley CR, Stoclet JC. High affinity bradykinin B2 receptor binding sites to guanine nucleotides in bovine aortic endothelial cells. *Eur J Pharmacol* 1991; 207: 149-155

Kessler DJ, Duyao MP, Spicer DB, Sonenshein GE. NF-*kappa* B like factors mediate interleukin 1 induction of c-myc gene transcription in fibroblasts. *J Exp Med* 1992; 176: 787-792

Klein I, Levey JS, Gondek M. Characterisation of the phosphoprotein in spontaneously beating cultured rat heart cells. *Procedures of the society for experimental biology and medicine* 1982; 170: 19-24

Kintsurashvili E, Duka I, Gavras I, Johns C, Famakiotis D, Gavras H. Effects of Ang II on bradykinin receptor gene expression in cardiomyocytes and vascular smooth muscle cells. *Am J Physiol* 2001; 281: H1778- H1783

Kospitprapa C, Ockaili RA, Kukreja RC. Bradykinin B2 receptor is involved in the late phase of preconditioning in rabbit heart. *J Mol Cell Cardiol* 2001; 33: 1355-1362

Lagneux C, Innocenti-Francillard P, Godin-Ribuot D, Bader M, Ribuot C. Heat stress-induced B1 receptor synthesis in the rat: an ex vivo study. *Br J Pharmacol* 1998; 125: 812-816.

Lamontagne D, Nadeau R & Adam A. Effect of enalaprilat on bradykinin and des-Arg9-bradykinin release following reperfusion of the iscemia rat heart. *Br J Pharmacol* 1995; 115: 476-478

Lamontagne D, Nakhostine N, Couture R, Nadeau R. Mechanism of kinin B1-receptor induced hypotension in the anesthetized dog. *J Cardiovasc Pharmacol* 1996; 28: 645-50

Leesar AM, Storddard MF, Manchikalapudi S, Bolli R. Bradykinin induced preconditioning in patients undergoing coronary angioplasty. *J Am Coll Cardiol* 1999; 34: 639-650

Lefer AM, Peck RC. Cardioprotective effects of enalapril in acute myocardial ischemia. *Pharmacology* 1984; 29: 61-69

Levinsky NG: The renal kallikrein-kinin system. *Circ Res* 1979; 44: 441-451

Linz W, Schölkens B. A specific B2 bradykinin receptor antagonist HOE 140 abolishes the antitrophic effect of ramipril. *Br J Pharmacol* 1992; 105: 771-772.

Linz W, Wiemer G, Gohlke P, Unger Th, Schölkens BA: Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. *Pharmacol Rev* 1995; 47 (1): 25-49

Liu YH, Yang XP, Mehta D, Bulagannawar M, Scicli GM, Carretero OA. Role of kinins in chronic feart failure and in the therapeutic effect of ACE inhibitors in kininogen-deficient rats. *AJP Circulatory Physiology* 2000; 278 (2): H507-H514

Lommi J, Pulkki K, Koskinen P, Naveri H, Karkonen M, and Kupari M Hemadynamic, neuroendocrine and metabolic correlates of circulating cytokine concentrations in congestive heart failure. *Eur Heart J* 1997; 18: 1620-1625

Louis J, Dell'Italia, Oparil S. Bradykinin in the Heart : Friend Or Foe? *Circulation* 1999; 100: 2305-2307

Lowry SF. Cytokine mediators of immunity and inflammation *Arch Surg* 1993; 28: 1235-1241

McDonald KM, Mock J, D'Aloia A, Parrish T, Hauer K, Francis G, Stillman A, Cohn JN. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. *Circulation* 1995; 91: 2043-2048

Madeddu P, Varoni MV, Palomba D, Emanueli C, Demontis MP, Glorioso N, Dessi-Fulgheri P, Sarzani R, Anania V, Cardiovascular phenotype of a mouse strain with disruption of the bradykinin B2-receptor gene. *Circulation* 1997; 96: 3570-3578

Madeddu P, Emanueli C, Gaspa L, Salis B, Milia AF, Chao L, Chao J. Role of the bradykinin B2 receptor in the muturation of blood pressure phenotype: Lesson from transgenenic and knockout mice. *Immunopharmacology* 1999; 44: 9-13

Mann DL, Young JB. Basic Mechanisms in Congestive heart Failure. Recognizing the Role of Proinflammatory Cytokines. *Chest* 1994;105: 897-904

Marceau F, Hess JF, and Bachvarov DR. Kinin B1 receptor. a review. *Immunopharmacology* 1995; 30: 1-26

Marcus C. Schaub Martin A. Hefti Beatrice A. Harder. Hans M. Eppenberger. Various hypertrophic stimuli induce distinct phentypes in cardiomyocytes. *J Mol Med* 1997; 75: 901-920

McCormick RJ, Mush TI, Bergman BC, Thomas DP, Reginol difference in LV collagen accumulation and mature cross-linking after myocardial infarction in rats. *Am J Physiol* 1994; 266: H354-H359

McLean PG, Perretti M, Ahluwalia A. Inducible expression of the kinin B1 receptor in the endotoxemic heart: mechanisms of des-Arg9bradykinin-induced coronary vasodilation. *Br J Pharmaco*l 1999; 128: 275-282

McLean PG, Perretti M, Ahluwalia A. Kinin B1 receptors and the cardiocascular system: regulation of expression and function. *Cardiovasc Res* 2000; 48: 194-210

Menke JG, Borkowski JA, Bierilo KK, MacNeil T, Derrick AW, Schneck KA, Ransom RW, Strader CD, Linemeyer DL,& Hess JF. Expression cloning of a human B1 bradykinin receptor. *J Biol Chem* 1994; 269: 21583-21586

Minshall RD, Nakamura F, Becker RP, Rabito SF. Characterization of bradykinin B2 receptor in adult myocardium and neonatal rat cardiomyocytes. *Circ Res* 1995; 76: 773-780

Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. *Circulation* 1986; 74: 1124-1136

Nancy J, Brown MD, Douglas E, Vaugham MD. Angiotensin-Converting Enzyme Inhibitors. *Circulation* 1998; 97: 1411-1420

Neumann FJ, Ott I, Gawaz M, Richardt G, Holzapfel H, Mochum, Schomig A. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. *Circulation* 1995; 92: 748-755

Ni A, Chao L, Chao J. Transcription factor nuclear factor Kappa B regulates the inducible expression of the human B1 receptor gene in inflammation. *J Biol Chem* 1998; 273: 2784-2791

Noda K, Sasaguri M, Ideishi M, Ikeda M, Arakawa K. Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. *Cardiovasc Res* 1993; 27 (2): 334-40.

Nolly H, Carbina LA, Scicili G, Carretero OA, Scicil AG. A local kallikrein-kinin system is present in rat hearts. *Hypertension* 1994; 23: 919-923

Okusawa S, Gelfand JA, Ikejima T, Connolly IJ, Dinarello CA. Interleulkin 1 induces a shock like state in rabbits: synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. *J Clin Invest* 1988; 81: 1162-72

Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Cytokine gene expression after myocardial infarction in rat hearts: Possible implication in left ventricular remodeling. *Circulation* 1998; 98: 149-156

Pagaelow I, Werner H, Vietinghof G, Wartner U. Release of cytokines from isolated lung stripes by bradykinin. *Inflamm Res* 1995; 44: 306-311

Pan ZK, Zuraw BL, Lung CC, Prossnitz ER, Browning DD, and Ye RD. Bradykinin stimulates NF-kappaB activation and interleukin 1 beta gene expression in cultured human fibroblasts. *J Clin Invest* 1996; 98: 2042-2049

Parratt JR, Vegh A, Zeitlin IJ, Ahmad M, Oldroyd K, Kaszala K, Papp JG. Bradykinin and endothelia-cardiac interations in ischemic preconditioning. *Am J Cardiol* 1997; 80 (3A): 124 A-131A

Pfeffer M, Braunwald E, Moye L, Basta L, Brown E, Cuddy T, Davis B, Geltman E, Goldman S, Flaker G. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. *N Engl J Med* 1992; 327: 669-77

Phagoo SB, Yaqoob M, Martinez EH, McIntyre P, Jones C, Burgess GM. Regulation of bradykinin receptor gene expression in human lung fibroblasts. *Eur J Pharmacol* 2000; 397: 237-246

Phagoo SB, Poole S, Leeb-Lundberg LMF. Autoregulation of bradykinin receptors: agonist in the presence of Interleukin 1ß shift the repertoire of receptor subtypes from B2 to B1 in human lung fibroblasts. *Mol Pharmacol* 1999; 56: 325-333

Philbin EF, Rocco TA. Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function. *Am Heart J* 1997;134 (2) Part 1: 188-195

Proud D, Kaplan AP. Kinin formation: mecanisms and role in inflammatory disorders. *Annu Rev Immunol* 1988: 6; 49-83

Pulkki KJ. Cytokines and cardiomyocyte death. *Cardiovascular Homeostasis* 1997; 29: 339-343

Pyne S, Yyne NJ. Differential effects of B2 receptor antagonists upon bradykinin-stimulated phopholipase C and D in guinea-pig cultured tracheal smooth muscle cells. *Br J Pharmacol* 1993; 110: 477-481

Regoli D, Jukic D, Gobeil F, Rhaleb NE. Receptors for bradykinin and related kinins: a critical analysis. *Can J Physiol Pharamco* 1993; 71: 556-67

Rehbock J, Miska K, Buchinger P. Induction of the bradykinin B2-receptor, but not of the B2 receptor, by IL1ß in cultivated human decidua-derived cells. *Immunopharmacology* 1999; 43(2-3): 235-9

Remme WJ. Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischemic therapy. *Drugs* 1997; 54 Suppl 5: 59-70

Repine JE. Oxidant-antioxidant balance: Some observations from studies of ischemia-reperfusion in isolated ferfused rat hearts. *Am J Med* 1991; 91(suppl 3C): 45-53S

Schmidlin F, Scherrer D, Daeffler L, Bertrand C, Landry Y, Gies J –P. Interleukin-1ß induces bradykinin B2 receptor gene expression through a prostanoid cyclie AMP-dependent pathway in human bronchial smooth muscle cells. *Mol Pharm* 1998; 53: 1009-1015

Schölkens BA, Linz W, König W. Effects of the angiotensin-converting enzyme inhibitor, ramipril, in isolated ischemic rat heart are abolished by a bradykinin antagonist. *J Hypertens* 1988 ; 6 (Suppl 4): 25-28

Scicli AG, Mindrooiu T, Scicli G, Carretero OA. Blood kinins, their concentrations in normal subjects and in patients with congenital deficiency in plasma prekallikrein and kininogen. *J Lab Clin Med* 1982; 100: 81-93

Seyedi N, Win T, Lander HM, Levi R. Bradykinin B2-receptor activation augments norepinephrine exocytosis from cardiac sympathetic nerve endings: mediation by autocrine/paracrine mechanisms. *Circ Res* 1997; 81: 774–784

SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. *N Engl J Med* 1992; 327: 685-91

Squire IB, O'Kane KP, Anderson N, Reid JL. Bradykinin B2 receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men. *Hypertension* 2000; 36: 132-136

Stauss HM, Zhu YC, Redlich T, Unger Th: Early and late treatment of infarction-induced heart failure with a converting enzyme inhibitor: Bradykinin potentiation versus angiotensin II reduction. *Hypertension* 1993; 22: 429

Stewart JM, Gera L, Hanson W, Zuzack JS, Burkard M, McCullough R, Whalley ET. A new generation of bradykinin antagonists. *Immunopharmacology* 1996; 33: 51-60

Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). *N Engl J Med* 1992; 327: 678-84

Tashiro H, Shimokawa H, Yamamoto K, Nagano N, Momohara M, Muramatu K, Takeshita A. Monocyte-related cytokines in acute myocardial infarction. *Am Heart J* 1995; 130 (3 Pt 1): 446-52

Tschöpe C, Walther SH, Koch M, Spillmann F, Wendorf M, Hauke D, Bader M, Schultheiss H –P, Walther T. Myocardial bradykinin B2-receptor expression at different time points after induction of myocardial infarction. *J Hypertens* 2000; 18: 223-228 *a*

Tschöpe C, Walther SH, Koch M, Spillmann F, Wendorf M, Leitner E, Schultheiss H –P, Walther T. Upregulation of bradykinin B1-receptor expression after myocardial infarction. *Br J Pharmacol* 2000; 129: 1537-1538 *b*

Walker K, Perkins M, Dray A. Kinins and kinin receptors in the nervous system. *Neurochem Int* 1995; 26: 1-16

Wang J, Xiong W, Yang Z, Davis T, Dewey MJ, Chao J, Chao L. Human tissue kallikrein induces hypotension in transgenic mice. *Hypertention* 1994; 23: 236-243

Willis LR, Luden JH, Hook JB, Williamson HE: Mechanism of natriuretic action of bradykinin. *Am J Physiol* 1969; 217: 1-5

Witherow FN, Helmy A, Webb DJ, Fox KAA, Newby DE. Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inibition in patients with heart failure. *Circulation* 2001; 104: 2177

Vouture R, Harrisson M, Vianna R M, Cloutier F. Kinin receptors in pain and inflammation. *Eur J Pharmacol* 2001; 429: 161-176

Yayama K, Nagaoka M, Takano M, Okamoto H. Expression of kininogen, kallikrein and kinin receptor genes by rat cardiomyocytes. *Biochimica et Biophysica Acta* 2000; 1495: 69-77

Yoshida H, Zhang JJ, Chao L, Chao J. Kallikrein Gene Delivery Attenuates Myocardial Infarction and apoptosis after myocardial Ischemia and Reperfusion. *Hypertension* 2000; 35 (1 Pt 1): 25-31

Yue P, Massie BM, Simpsin PC, Long CS. Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure. *AM J Physio* 1998; 275: H250-H258

Zhou X, Polgar P, Taylor L. Roles for interleukin-1beta, phorbol ester and a post-transcriptional regulator in the control of bradykinin B1 receptor gene expression. *Biochem Journa*l 1998; 330: 361-366

Zisman LS. Inhibiting tissue angiotensin-converting enzyme: a pound of flesh without the blood? *Circulation* 1998; 98: 2788-2790

7. Curriculum vitae

Name:	Yang jianchang
Day of birth	17.10.1971
Place of Birth:	Shandong Province, People's Republic of China
Marital state:	Single

Education

Graduate education:	Sep. 1988 – Jul. 1993 Xinjiang University of Medical Sciences Urumqi, Xinjiang P.R.China
Postgraduate education:	Aug. 1994 – Jul. 1997 **Master Thesis** Supervisor: Prof. Wu Xinyao Subject: Biochemistry /Medicine Sun yatsen University of Medical Sciences Guangzhou, P.R. China

Publication:

A new technique for detecting human DNA fingerprint.
Yang JC, Wu XY.New Medicine.1997; 22: 45-46

Apr. 2001-

M.D Thesis

Supervisor:Carsten Tschöpe M.D; Thomas Walther Ph.D
University Hospital Benjamin Franklin, Free University Berlim

Professional Experience

Aug. 1993 – Jul. 1994
Clinical doctor
Xinjiang Iron&Steel Company Affiliated Hospital
Urumqi P.R. China

Aug. 1997 – Jul. 1999
Research Group Prof. Luo Chaoquan
Department of Biochemidtry
Sun yatsen University of Medical Sciences
Guangzhou, P.R. China